Certainly in a transgenic mouse model of AD, the introduction of a human mutant α‐synuclein transgene promoted both the Αβ and tau pathology and also accelerated the cognitive decline, pointing to a synergistic effect 9. This evidence concerns the gene MAPT and Alzheimer disease.